Denali Therapeutics price to sales ratio DNLI

Market value divided by revenue over the last twelve months, since 2019.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 11.6×; Jul 2024
8-year median: 19.4×
8-year range: 6.5× to 169×
Peer median: 6.8×

Denali Therapeutics' price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.

It was last meaningful in Jul 2024, at 11.6×.

On the days it had one over the last 8 years, its median was 19.4×, from 6.5× in Apr 2024 to 169× in Oct 2020.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2024	11.6×	6.5×	11.6×
2023	8.7×	6.6×	42.6×
2022	34.1×	11.2×	88.7×
2021	15.4×	14.7×	27.4×
2020	164×	10.5×	169×
2019	11.9×	9.6×	20.6×

Against its peers

Companies in Biotechnology nearest Denali Therapeutics' size, closest first, today.

Company	Price to sales ratio
DNLIDenali Therapeutics	n/m
ADMAAdma Biologics	4.7×
VCELVericel	7.1×
KRYSKrystal Biotech	20.9×
MGTXMeiraGTx	2.2×
RGENRepligen	12.7×
TECHBIO-TECHNE	9.4×
HALOHalozyme Therapeutics	8.6×
NBIXNeurocrine Biosciences	4.3×
EXELExelixis	6.6×
INCYIncyte	4.0×
Peer median	6.8×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Denali Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.